Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - MABVAX THERAPEUTICS HOLDINGS, INC. | d787227dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 10, 2014
MABVAX THERAPEUTICS HOLDINGS, INC.
(Exact Name of Registrant as Specified in its Charter)
| Delaware | 000-31265 | 93-0987903 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
11588 Sorrento Valley Rd., Suite 20
San Diego, CA 92121
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: (858) 259-9405
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Forward-Looking Statements
Statements contained in this Current Report on Form 8-K relating to MabVax’s or management’s intentions, hopes, beliefs, expectations or predictions of the future, including statements relating to the combined company’s management and board of directors and any other statements about our management team’s future expectations, beliefs, goals, plans or prospects are forward-looking statements. Our actual results could differ materially from those projected in these forward-looking statements. Additional factors that could cause actual results to differ materially from those described in the forward-looking statements are set forth in the Proxy Statement dated July 25, 2014, as amended and supplemented from time to time and in our reports on Forms 10-K, 10-Q and 8-K and other filings made with the SEC. We disclaim any intention or obligation to revise or update any forward-looking statements, including financial estimates, whether as a result of new information, future events or otherwise.
| Item 8.01. | Other Items. |
MabVax issued the press release attached to this Current Report as Exhibit 99.1 on September 10, 2014 announcing its entry into certain agreements with Memorial Sloan Kettering Cancer Center and Juno Therapeutics.
| Item 9.01. | Financial Statements and Exhibits. |
| Exhibit Number |
Description | |
| 99.1 | Press Release dated September 10, 2014 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MABVAX THERAPEUTICS HOLDINGS, INC. | ||||||
| Date: September 10, 2014 | By: | /s/ J. David Hansen | ||||
| J. David Hansen | ||||||
| President and Chief Executive Officer | ||||||
Exhibit Index
| Exhibit Number |
Description | |
| 99.1 | Press Release dated September 10, 2014 | |